tobramycin has been researched along with Chronic Kidney Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelnabi, M; Pai, MP; Sitaruno, S | 1 |
| Durham, ME; Gilstrap, DL; Green, CL; Kram, BL; Kram, SJ; Kuhrt, M; Parish, A; Schultheis, JM | 1 |
| Abdel, MP; Berry, DJ; Dagneaux, L; Leung, N; Limberg, AK; Osmon, DR | 1 |
| Larmour, I; Lim, AK; Mathanasenarajah, G | 1 |
| Bennett, MR; Clancy, JP; Dong, M; Downes, KJ; Fukuda, T; Goldstein, SL; Haffner, C; Vinks, AA | 1 |
| Cottingham, L; Langley, A | 1 |
6 other study(ies) available for tobramycin and Chronic Kidney Diseases
| Article | Year |
|---|---|
Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Body Surface Area; Creatinine; Gentamicins; Glomerular Filtration Rate; Humans; Kidney; Renal Insufficiency, Chronic; Tobramycin | 2023 |
Incidence and associated risk factors for systemic drug levels with inhaled aminoglycoside therapy.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Incidence; Renal Insufficiency, Chronic; Retrospective Studies; Tobramycin | 2023 |
Acute Kidney Injury When Treating Periprosthetic Joint Infections After Total Knee Arthroplasties with Antibiotic-Loaded Spacers: Incidence, Risks, and Outcomes.
Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Aged, 80 and over; Amphotericin B; Anti-Bacterial Agents; Arthroplasty, Replacement, Knee; Bone Cements; Creatinine; Disease Progression; Drug Implants; Female; Follow-Up Studies; Gentamicins; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Odds Ratio; Prosthesis-Related Infections; Renal Insufficiency, Chronic; Retrospective Studies; Risk; Risk Factors; Tobramycin; Treatment Outcome; Vancomycin | 2021 |
Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Gentamicins; Glomerular Filtration Rate; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Renal Insufficiency, Chronic; Tobramycin; Young Adult | 2015 |
Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.
Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Biomarkers; Bronchopneumonia; Child; Creatinine; Cystic Fibrosis; Drug Monitoring; Female; Hepatitis A Virus Cellular Receptor 1; Hospitals, Pediatric; Humans; Lipocalin-2; Male; Metabolic Clearance Rate; Ohio; Pilot Projects; Prospective Studies; Renal Insufficiency, Chronic; Retinol-Binding Proteins; Tobramycin; Young Adult | 2017 |
Detectable serum tobramycin concentrations in a patient with renal dysfunction receiving tobramycin by inhalation.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Humans; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Renal Insufficiency, Chronic; Tobramycin | 2011 |